Hypercholesterolemia clinical trials

Explore recruiting hypercholesterolemia clinical trials.

Recruiting hypercholesterolemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hypercholesterolemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter, 12-Week Trial to Evaluate the Efficacy and Safety of Treatment with K-924 HD in Participants with Hypercholesterolemia with Inadequate Response to EU-Marketed Pitavastatin 4 mg

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Open-label Extension Study to Evaluate the Safety and Efficacy of MK-0616 in Adults With Hypercholesterolemia

Finland, Italy, Czechia, France, Norway, Netherlands +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-0616 Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia

Spain, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

MK-7091 Formulations Study in Healthy Adult Participants

Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Low-Density Lipoprotein Cholesterol in Patients With Elevated Low-Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event

Bulgaria, Poland, Slovakia, Hungary, Czechia, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy, safety, tolerability and quality of life of ongoing individually optimized lipid-lowering therapy with or without inclisiran (KJX839) – a randomized, placebo-controlled, double-blind multicenter phase IV study in participants with hypercholesterolemia

Bulgaria, Poland, France, Estonia, Latvia, Czechia +2 more

Therapeutic use (Phase IV) EU CTIS Study details

Hypercholesterolemia trials by city

Hypercholesterolemia in Toronto Hypercholesterolemia in Vancouver Hypercholesterolemia in Montreal Hypercholesterolemia in Calgary Hypercholesterolemia in Edmonton Hypercholesterolemia in Ottawa Hypercholesterolemia in Winnipeg Hypercholesterolemia in Quebec City Hypercholesterolemia in Hamilton Hypercholesterolemia in Kitchener Hypercholesterolemia in London Hypercholesterolemia in Halifax Hypercholesterolemia in New York Hypercholesterolemia in Los Angeles Hypercholesterolemia in Chicago Hypercholesterolemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease